Acute myelocytic leukemia. 1976

J F Holland, and O Glidewell, and R R Ellison, and R W Corey, and J Schwartz, and H J Wallace, and H C Hoagland, and P Wiernik, and K Rai, and J G Bekesi, and J Cuttner

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D009163 Mycobacterium bovis The bovine variety of the tubercle bacillus. It is called also Mycobacterium tuberculosis var. bovis. BCG,Calmette-Guerin Bacillus
D009439 Neuraminidase An enzyme that catalyzes the hydrolysis of alpha-2,3, alpha-2,6-, and alpha-2,8-glycosidic linkages (at a decreasing rate, respectively) of terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid, and synthetic substrate. (From Enzyme Nomenclature, 1992) Sialidase,Exo-alpha-Sialidase,N-Acylneuraminate Glycohydrolases,Oligosaccharide Sialidase,Exo alpha Sialidase,Glycohydrolases, N-Acylneuraminate,N Acylneuraminate Glycohydrolases,Sialidase, Oligosaccharide
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

J F Holland, and O Glidewell, and R R Ellison, and R W Corey, and J Schwartz, and H J Wallace, and H C Hoagland, and P Wiernik, and K Rai, and J G Bekesi, and J Cuttner
December 1972, Cancer,
J F Holland, and O Glidewell, and R R Ellison, and R W Corey, and J Schwartz, and H J Wallace, and H C Hoagland, and P Wiernik, and K Rai, and J G Bekesi, and J Cuttner
February 1970, JAMA,
J F Holland, and O Glidewell, and R R Ellison, and R W Corey, and J Schwartz, and H J Wallace, and H C Hoagland, and P Wiernik, and K Rai, and J G Bekesi, and J Cuttner
January 1955, Archivio di ostetricia e ginecologia,
J F Holland, and O Glidewell, and R R Ellison, and R W Corey, and J Schwartz, and H J Wallace, and H C Hoagland, and P Wiernik, and K Rai, and J G Bekesi, and J Cuttner
January 1978, The Turkish journal of pediatrics,
J F Holland, and O Glidewell, and R R Ellison, and R W Corey, and J Schwartz, and H J Wallace, and H C Hoagland, and P Wiernik, and K Rai, and J G Bekesi, and J Cuttner
January 1989, Nordisk medicin,
J F Holland, and O Glidewell, and R R Ellison, and R W Corey, and J Schwartz, and H J Wallace, and H C Hoagland, and P Wiernik, and K Rai, and J G Bekesi, and J Cuttner
July 1972, New York state journal of medicine,
J F Holland, and O Glidewell, and R R Ellison, and R W Corey, and J Schwartz, and H J Wallace, and H C Hoagland, and P Wiernik, and K Rai, and J G Bekesi, and J Cuttner
April 1990, Leukemia,
J F Holland, and O Glidewell, and R R Ellison, and R W Corey, and J Schwartz, and H J Wallace, and H C Hoagland, and P Wiernik, and K Rai, and J G Bekesi, and J Cuttner
November 1978, Blood,
J F Holland, and O Glidewell, and R R Ellison, and R W Corey, and J Schwartz, and H J Wallace, and H C Hoagland, and P Wiernik, and K Rai, and J G Bekesi, and J Cuttner
June 1978, The New England journal of medicine,
J F Holland, and O Glidewell, and R R Ellison, and R W Corey, and J Schwartz, and H J Wallace, and H C Hoagland, and P Wiernik, and K Rai, and J G Bekesi, and J Cuttner
January 1989, Journal of clinical epidemiology,
Copied contents to your clipboard!